Episode 5 – Biosimilars and MS: improving access to high-efficacy treatment
01 września 2025
In Episode 5 of the Illuminoz podcast series, Sim Trivedy speaks with Dr. Barbara Kornek – neurologist and President of the Vienna MS Society – about the potential of biosimilars to improve access to high-efficacy treatments in multiple sclerosis.
Why is early intervention so critical in MS? What barriers—regulatory, financial, and clinical—still limit access to optimal care? And how can biosimilars help bridge the gap between innovation and availability?
This episode offers expert insights, real-world data, and a hopeful outlook on making effective MS therapies more accessible.
Informacje o podcaście:
“Illuminoz talks 2025” podcast series:
Episode 12 – PML: what is it, and why is it relevant in MS?
dr Tobias Bopp,
Episode 11 – Introducing biosimilar natalizumab
dr Heinz Wiendl,
Episode 10 – Patient conversations part three: the patient perspective
Ellen Tutton,
Episode 9 – Patient conversations part two: the nurse perspective
karolinamalicka,
Episode 8 – Patient conversations part one: the neurologist perspective
dr Agne Straukiene,
Episode 7 – Lessons learned part two: the value of biosimilars in rheumatology
prof. Paul Emery,
Episode 6 – Lessons learned part one: the value of biosimilars in oncology
prof. Kai Hübel,
Episode 4 – Treatment paradigms in MS: right patient, right treatment, right time
dr Laura Airas,
Episode 3 – MS treatment landscape part two: potential role of biosimilars
dr David Paling,
Episode 2 – MS treatment landscape part one: unmet needs
dr Luisa Klotz,
Episode 1 – Biosimilars: what are they, and why might they be important for MS?
dr Wallace Brownlee,
